Efficacy of Statin/Ezetimibe for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Asian Populations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials-Reference-Cited by-同舟云学术

Efficacy of Statin/Ezetimibe for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Asian Populations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Published:2020-07-15 Issue:9 Volume:40 Page:809-826
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Bhagavathula Akshaya Srikanth^ORCID,Aldhaleei Wafa Ali,Al Matrooshi Nadya Obaid,Rahmani Jamal

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-020-00951-1.pdf

Reference50 articles.

1. Gidding SS, Allen NB. Cholesterol and atherosclerotic cardiovascular disease: a lifelong problem. J Am Heart Assoc. 2019;8:e012924. https://doi.org/10.1161/JAHA.119.012924.

2. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302–9. https://doi.org/10.1001/jama.2012.366.

3. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81. https://doi.org/10.1093/eurheartj/ehw106.

4. Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25:846–98484. https://doi.org/10.5551/jat.GL2017.

5. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68:92–125. https://doi.org/10.1016/j.jacc.2016.03.519.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials;Phytomedicine;2023-04

2. The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials;Inflammopharmacology;2022-08-21

3. Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction;Lipids in Health and Disease;2021-09-29

4. Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia;Expert Review of Cardiovascular Therapy;2021-06-15

5. Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles;Lipids in Health and Disease;2021-05-06